Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery.
Open Access
- 1 August 1979
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 64 (2) , 684-688
- https://doi.org/10.1172/jci109509
Abstract
The present study describes a canine model of transient reversible blood-brain barrier disruption with hyperosmolar mannitol infusion into the internal carotid artery. Studies in this model show that osmotic blood-brain barrier disruption before intracarotid infusion of methotrexate results in markedly elevated (therapeutic) levels of drug in the ipsilateral cerebral hemisphere. Levels in the cerebrospinal fluid correlate poorly and inconsistently with brain levels. Computerized tomograms in this canine model provide a noninvasive monitor of the degree, time-course, and localization of osmotic blood-brain barrier disruption. Images.This publication has 10 references indexed in Scilit:
- Direct administration of methotrexate into the central nervous system of primatesJournal of Neurosurgery, 1978
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977
- Chemotherapy of Brain TumorsArchives of Neurology, 1977
- Management of central nervous system metastases.1977
- Methotrexate in blood, urine, and cerebrospinal fluid of children receiving high doses by infusion.Clinical Chemistry, 1976
- Methotrexate: Distribution in Cerebrospinal Fluid after Intravenous, Ventricular and Lumbar InjectionsNew England Journal of Medicine, 1975
- Equi-Osmolal Opening of the Blood-Brain Barrier in the Rabbit by Different Contrast MediaActa Radiologica. Diagnosis, 1974
- Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high-dosage scheduleCancer, 1974
- Chemotherapy of brain tumorsJournal of Neurosurgery, 1972
- Uptake and Distribution of 3H-Methotrexate by the Murine EpendymoblastomaJNCI Journal of the National Cancer Institute, 1972